Aslan's Dupixent rival test put on hold amid COVID-19, but delays shouldn't hit readout

Aslan Pharmaceuticals has seen multiple trial flops, restructuring and cuts over the past few years; now, it has been beset by pandemic woe.

The Singapore company said Monday morning that ASLAN004, the anti-IL-13Rα1 antibody licensed from CSL it's positioned to try to take on Regeneron and Sanofi’s blockbuster Dupixent, has seen patient recruitment paused for an ongoing test in severe atopic dermatitis.